

EASTWOOD BIO-MEDICAL CANADA INC.

#1130 - 4871 Shell Road
Richmond, British Columbia
V6X 3Z6

TSX-V: EBM

NEWS RELEASE

Eastwood Bio-medical Canada Inc. Introduces New Cannabis and Cholesterol Products

September 5, 2018 – Richmond, British Columbia – Eastwood Bio-medical Canada Inc. (TSX-V: EBM) (the “Company”) is pleased to announce Health Canada has granted further new Natural Product Numbers (NPNs) for the following products:

Eleotin HepaBene, for liver health.

Eleotin Solomon, a cannabis product for improving mental performance.

Eleotin Philosophy, a cannabis product for enhancing cognitive functions.

Eleotin R-square C1 Formula, for lowering cholesterol.

Yunji Kim, President and CEO, commented, “It’s an exciting time for us. We are branching out into providing the market with novel formulations made with the finest ingredients in the market. We have been aggressively adding to our portfolio of products, and look forward to serving a wider target market.”

About Eastwood Bio-Medical Canada, Inc.:

The Company is a Vancouver based biotechnology company whose Eleotin[®] brand of products provide natural sourced solutions for metabolic syndromes such as blood glucose control, obesity, and hypertension.

Eleotin[®] was initially developed by the scientists at the Julia McFarlane Diabetes Research Center (JMDRC) at the University of Calgary in Alberta, Canada. The JMDRC is a leader in research on the cause, cure, and prevention of Type I and Type II diabetes. After the initial development by the JMDRC, research and development were continued by Eastwood Bio-medical Research Inc., the Company, and other institutions around the world, including Tsinghua University of the People’s Republic of China. Eleotin[®] products have been endorsed by thousands of doctors and diabetes associations around the globe.

More information on Eastwood Bio-Medical Canada Inc., can be found on the website www.eleotin.ca.

For further information, please contact:

Eastwood Bio-Medical Canada Inc.

Yunji Kim, President and Chief Executive Officer

Telephone: (604) 247-2100

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forwardlooking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. There is no assurance that the new products will produce the revenue increase the Company expects. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.